DURHAM, NC – LipoScience is filing to go public. The company, which last tried to go public in June 2011, hopes to raise more than $70 million based on an securities filing.
LipoScience would trade under the symbol LPDX.
The company has set a target price of between $13 and $15 a share. It’s offering 5 million shares, with an overallotment option for underwriters of 750,000 shares.
If underwriters take the option and the stock sells for $14 a share, the proceeds would be about $71 million.
Underwriters include Barclays (NYSE: BCS), UBS Investment Bank and Piper Jaffray (NYSE: PJC).
Net proceeds would go toward hiring sales and marketing support costs, capital expenditures and research and development.
The company’s first diagnostic test, the NMR LipoProfile test, which measures lipoprotein, a risk factor for heart disease, has already netted more than 8 million orders.